Elicitation of Health State Utility Values in Retinitis Pigmentosa by Time Trade-off in the United Kingdom

References

• Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809.
   PubMed Web of Science ®Google Scholar
• Lange R, Kumagai A, Weiss S, et al. Vision-related quality of life in adults with severe peripheral vision loss: a qualitative interview study. J Patient-Rep Outcomes. 2021;5(1):1–12. doi:10.1186/s41687-020-00281-y
   PubMedGoogle Scholar
• American Academy of Opthalmology. New treatments for retinitis pigmentosa; 2021. Available from: https://www.aao.org/eye-health/tips-prevention/gene-therapy-new-retinitis-pigmentosa-lca-luxturna. Accessed December 28, 2022.
   Google Scholar
• Ahmed I, Johnston Jr RJ Jr, Singh MS. Pluripotent stem cell therapy for retinal diseases. Ann Transl Med. 2021;9(15):1279. doi:10.21037/atm-20-4747
   PubMed Web of Science ®Google Scholar
• Nuzbrokh Y, Ragi SD, Tsang SH. Gene therapy for inherited retinal diseases. Ann Transl Med. 2021;9(15):1278. doi:10.21037/atm-20-4726
   PubMed Web of Science ®Google Scholar
• Hinkle JW, Mahmoudzadeh R, Kuriyan AE. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer “cell therapy” clinics. Stem Cell Res Ther. 2021;12(1):1–9. doi:10.1186/s13287-021-02546-9
   PubMed Web of Science ®Google Scholar
• Banhazi J, Williamson N, Bradley H, et al. What Do We Know About Patients’ and Caregivers’ Experiences When Living with the Hereditary Retinal Condition Retinitis Pigmentosa? Copenhagen, Denmark: ISPOR EU; 2019.
   Google Scholar
• Sallum J, Kaur V, Shaikh J, et al. Epidemiology of mutations in the 65-kDa Retinal Pigment Epithelium (RPE65) gene-mediated inherited retinal dystrophies: a systematic literature review. Adv Ther. 2022;39:1179–1198. doi:10.1007/s12325-021-02036-7
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21. doi:10.1093/bmb/ldq033
   PubMed Web of Science ®Google Scholar
• Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. 2019;103(11):1610–1614.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013–5 the reference case; 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case. Accessed December 28, 2022.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Canada; 2017. Available from: https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Accessed December 28, 2022.
   Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Proposal for a guide for economic evaluation applied to health technologies. Gac Sanit. 2010;24(2):154–170. doi:10.1016/j.gaceta.2009.07.011
   PubMed Web of Science ®Google Scholar
• Merlin T, Tamblyn D, Schubert C. Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0. Australian Government, Department of health; 2016.
   Google Scholar
• China Guidelines for Pharmacoeconomic Evaluations Working Group. China guidelines for pharmacoeconomic evaluations; 2020 Available from: https://tools.ispor.org/PEguidelines/source/China-Guidelines-for-Pharmacoeconomic-Evaluations-2020.pdf. Accessed December 28, 2022.
   Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health. 2017;20(3):372–378. doi:10.1016/j.jval.2016.08.726
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values. National Institute for Health and Care Excellence; 2011.
   Google Scholar
• Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18(1):63. doi:10.1186/s12913-018-2836-0
   PubMed Web of Science ®Google Scholar
• Oppe M, Rand-Hendriksen K, Shah K, Ramos‐Goñi JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics. 2016;34(10):993–1004. doi:10.1007/s40273-016-0404-1
   PubMed Web of Science ®Google Scholar
• Nomis. Population estimates - local authority based by single year of age; 2018. Available from: https://www.nomisweb.co.uk/livelinks/13687.xlsx. Accessed December 28, 2022.
   Google Scholar
• Office for National Statistics. 2011 Census; 2011. Available from: https://www.ons.gov.uk/census/2011census. Accessed December 28, 2022.
   Google Scholar
• Office for National Statistics. Employment in the UK; 2019. Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/employmentintheuk/december2019. Accessed December 28, 2022.
   Google Scholar
• Office for National Statistics. Highest level of qualification achieved by people living in UK regions, 2010 to 2018; 2019. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/educationandchildcare/adhocs/10516highestlevelofqualificationachievedbypeoplelivinginukregions2010to2018. Accessed December 28, 2022.
   Google Scholar
• Office for National Statistics. Population estimates by marital status and living arrangements, England and Wales; 2019. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesbymaritalstatusandlivingarrangements. Accessed December 28, 2022.
   Google Scholar
• Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2018; 2019. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/latest. Accessed December 28, 2022.
   Google Scholar
• Janssen B, Szende A; Population norms for the EQ-5D. Self-Reported Population Health: An International Perspective Based on EQ-5D. Springer Nature; 2014:19–30.
   Google Scholar
• Goodwin E, Green C, Hawton A. What difference does it make? A comparison of health state preferences elicited from the general population and from people with multiple sclerosis. Value Health. 2020;23(2):242–250. doi:10.1016/j.jval.2019.08.009
   PubMed Web of Science ®Google Scholar
• Castejón N, Cappelleri JC, Cuervo J, et al. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom. Health Qual Life Outcomes. 2018;16(1):1–9. doi:10.1186/s12955-018-0897-8
   PubMedGoogle Scholar
• Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12(5):793–799. doi:10.1111/j.1524-4733.2009.00527.x
   PubMed Web of Science ®Google Scholar
• Rentz AM, Kowalski JW, Walt JG, et al. Development of a preference-based index from the national eye institute visual function questionnaire-25. JAMA Ophthalmol. 2014;132(3):310–318. doi:10.1001/jamaophthalmol.2013.7639
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128(3):324–330. doi:10.1016/S0002-9394(99)00146-4
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Busbee B. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology. 2003;110(6):1076–1081. doi:10.1016/S0161-6420(03)00254-9
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations; 2019. Available from: https://www.nice.org.uk/guidance/hst11. Accessed December 28, 2022.
   Google Scholar
• Na KH, Kim HJ, Kim KH, et al. Prevalence, age at diagnosis, mortality, and cause of death in retinitis pigmentosa in Korea-A nationwide population-based study. Am J Ophthalmol. 2017;176:157–165. doi:10.1016/j.ajo.2017.01.014
   PubMed Web of Science ®Google Scholar
• Prem Senthil M, Khadka J, Pesudovs K. Seeing through their eyes: lived experiences of people with retinitis pigmentosa. Eye. 2017;31(5):741–748. doi:10.1038/eye.2016.315
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé. Choices in methods for economic evaluation; 2012. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf. Accessed December 28, 2022.
   Google Scholar
• Institute for Clinical and Economic Review. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value - final evidence report; 2018. Available from: https://icer.org/wp-content/uploads/2020/10/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf. Accessed December 28, 2022.
   Google Scholar
• Tolley K What are health utilities? 2009. Available from: http://www.bandolier.org.uk/painres/download/What%20is%202009/What_are_health_util.pdf. Accessed December 28, 2022.
   Google Scholar
• Brazier J, Rowen D, Karimi M, Peasgood T, Tsuchiya A, Ratcliffe J. Experience-based utility and own health state valuation for a health state classification system: why and how to do it. Eur J Health Econ. 2018;19(6):881–891. doi:10.1007/s10198-017-0931-5
   PubMed Web of Science ®Google Scholar